Claritas Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLAZF research report →
Price Chart
About the company
Operating as a clinical-stage specialty pharmaceutical entity, Claritas Pharmaceuticals, Inc. is dedicated to the creation and market introduction of medical therapies addressing significant patient needs that are currently unfulfilled. Established in 2014, the company was previously known as Kalytera Therapeutics, Inc.
- CEO
- Robert Farrell
- IPO
- 2016
- Employees
- 3
- HQ
- San Rafael, CA, US
Get TickerSpark's AI analysis on CLAZF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.66K
- P/E
- 0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.05
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -436.27%
- ROIC
- 482.39%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-3,276,000
- Net Income
- $4.21M+119.8%
- EPS
- $0.16+116.8%
- OCF Growth
- +95.2%
- FCF Growth
- +95.2%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.12
- RSI (14)
- 31
- Avg Volume
- 250
No earnings-call transcripts are available for CLAZF yet.
- Free Float
- 83.2%
- Shares Outstanding
- 36.59M
- Float Shares
- 30.44M
Our CLAZF coverage
Recent articles, reports, and earnings notes.
No research on CLAZF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLAZF report →